Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Public ClinicalTrials.gov record NCT04564339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Study identification
- NCT ID
- NCT04564339
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 123 participants
Conditions and interventions
Conditions
Interventions
- Ravulizumab Drug
- Placebo Drug
- Background Therapy Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 18, 2021
- Primary completion
- Mar 25, 2025
- Completion
- Aug 17, 2025
- Last update posted
- Jan 21, 2026
2021 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | San Dimas | California | 91773 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | South Gate | California | 90280 | — |
| Research Site | Stanford | California | 94305 | — |
| Research Site | Orlando | Florida | 32835 | — |
| Research Site | Plantation | Florida | 33324 | — |
| Research Site | Lawrenceville | Georgia | 30046 | — |
| Research Site | Lexington | Kentucky | 40536 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Boston | Massachusetts | 02115 | — |
| Research Site | Kansas City | Missouri | 64111 | — |
| Research Site | New York | New York | 10003 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | Columbus | Ohio | 43203 | — |
| Research Site | El Paso | Texas | 79935 | — |
| Research Site | Houston | Texas | 77054 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04564339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 21, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04564339 live on ClinicalTrials.gov.